share_log

百时美施贵宝(BMY.US)就炎症性肠病治疗与GentiBio达成合作 协议金额最高达19亿美元

Bristol-Myers Squibb (BMY.US) reached a cooperation agreement with GenTiBio on the treatment of inflammatory bowel disease for a maximum amount of 1.9 billion US dollars

Zhitong Finance ·  Aug 10, 2022 20:05

The Zhitong Finance App learned that on August 10, Bristol-Myers Squibb (BMY.US) announced a collaboration with GentiBio to develop regulatory T cell (Treg) therapy for inflammatory bowel disease (IBD).

Over many years of collaboration, GenTiBio will use its modular engineering Treg platform and scalable manufacturing processes to produce stable and disease-specific engineered Treg for multiple targets. Bristol-Myers Squibb will have the right to develop and advance three of these projects into clinical trials.

Bristol-Myers Squibb prepaid GenTiBio an undisclosed amount of cash. Additionally, GenTiBio is eligible for development and sales milestone payments and royalties of up to $1.9 billion.

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment